PRODUCT INFORMATION
ALC-0315

Item No. 34337
CAS Registry No.: 2036272-55-4
Formal Name:
2-hexyl-decanoic acid,
1,1’-[[(4-hydroxybutyl)imino]di-6,1- HO
hexanediyl] esterMF:
C48H95NO5
FW:
766.3
Purity:≥98%
Supplied as:
A solution in ethanol
Storage:-20°C
Stability:≥2 years

ONOOO

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures
ALC-0315 is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol undera gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as chloroform purged
with an inert gas can be used. The solubility of ALC-0315 in chloroform is approximately 50 mg/ml.
Description
ALC-0315 is an ionizable cationic lipid (pKa 6.09) that has been used in the generation of lipid nanoparticles(LNPs) for the delivery of mRNA, siRNA, and plasmid DNA in vitro and in vivo.1-4 LNPs containing
ALC-0315 and encapsulating siRNA targeting Factor VII mRNA decrease Factor VII mRNA levels inhepatocytes in mice.3 Administration of severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA inALC-0315-containing LNPs induces the production of IgG that binds to the SARS-CoV-2 receptor-binding
domain (RBD) in rhesus macaques, with a boost in antigen-specific IgG geometric mean titers (GMT) sevenand 14 days after a second dose. LNPs containing ALC-0315 and encapsulating ovalbumin mRNA reducetumor volume in an ovalbumin-expressing B16/F10 murine melanoma model.5 Formulations containing
ALC-0315 have been used in the development of LNPs for the delivery of mRNA-based vaccines.
References
1. Ansell, S.M. and Du, X. Lipids and lipid nanoparticle formulations for delivery of nucleic acids.
Acuitas Therapeutics, Inc. US 10,166,298 B2, (2019).
2. Vogel, A.B., Kanevsky, I., Che, Y., et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Nature 592(7853), 283-289 (2021).
3. Ferraresso, F., Strilchuk, A.W., Juang, L.J., et al. Comparison of DLin-MC3-DMA and ALC-0315 for siRNAdelivery to hepatocytes and hepatic stellate cells. Mol. Pharm. 19(7), 2175-2182 (2022).
4. Zhang, W., Pfeifle, A., Lansdell, C., et al. The expression kinetics and immunogenicity of lipid nanoparticles
delivering plasmid DNA and mRNA in mice. Vaccines (Basel) 11(10), 1580 (2023).
5. Chen, J., Ye, Z., Huang, C., et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA
cancer vaccine elicits robust CD8+ T cell response. Proc. Natl. Acad. Sci. USA 119(34), e2207841119(2022).

WARNINGTHIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.
SAFETY DATAThis material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly afterhandling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.
WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman’s Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information
can be found on our website.
Copyright Cayman Chemical Company, 08/12/2024

CAYMAN CHEMICAL1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM